Collaborative Network for Clinical Research on Immune Tolerance
This grant supports clinical trials and research to improve understanding and treatment of immune tolerance in transplant rejection, autoimmune, allergic diseases, and asthma.
This grant was recently updated
This grant has transitioned from forecasted to posted and is now accepting applications.
Funder: National Institutes of Health
Due Dates: January 29, 2027 (Applications)
Funding Amounts: $21,986,000 estimated total program funding; 1 award expected
Summary: Supports continuation of the Immune Tolerance Network to develop tolerogenic therapies through clinical trials and integrated mechanistic studies.
Key Information: Clinical trials are required under this UM1 cooperative agreement opportunity.
Description
The National Institutes of Health (NIH) supports continuation of the Immune Tolerance Network (ITN), whose primary objective is to develop tolerogenic therapies for immune-mediated disorders. This opportunity uses the UM1 cooperative agreement mechanism and requires clinical trials. It focuses on three clinical areas: allergic diseases and asthma, autoimmune diseases, and the immune-mediated consequences of transplantation.
The Network’s core functions include designing and conducting clinical trials, sharing their results, and performing integrated mechanistic studies. The opportunity therefore supports the continuation of a network combining clinical investigation with mechanistic research across these areas of immune-mediated disease.
